Abstract:The chemokines/chemokine receptors pathway significantly influences cell migration, particularly in recruiting immune cells to the tumor microenvironment (TME), impacting tumor progression and treatment outcomes. Emerging research emphasizes the involvement of chemokines in drug resistance across various tumor therapies, including immunotherapy, chemotherapy, and targeted therapy. This review focuses on the role of chemokines/chemokine receptors in pancreatic cancer (PC) development, highlighting their impact on TME remodeling, immunotherapy, and relevant signaling pathways. The unique immunosuppressive microenvironment formed by the interaction of tumor cells, stromal cells and immune cells plays an important role in the tumor proliferation, invasion, migration and therapeutic resistance. Chemokines/chemokine receptors, such as chemokine ligand (CCL) 2, CCL3, CCL5, CCL20, CCL21, C-X-C motif chemokine ligand (CXCL) 1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL17, and C-X3-C motif chemokine ligand (CX3CL)1, derived mainly from leukocyte cells, cancer-related fibroblasts (CAFs), pancreatic stellate cells (PSCs), and tumor-associated macrophages (TAMs), contribute to PC progression and treatment resistance. Chemokines recruit myeloid-derived suppressor cells (MDSC), regulatory T cells (Tregs), and M2 macrophages, inhibiting the anti-tumor activity of immune cells. Simultaneously, they enhance pathways like epithelial-mesenchymal transition (EMT), Akt serine/threonine kinase (AKT), extracellular regulated protein kinases (ERK) 1/2, and nuclear factor kappa-B (NF-κB), etc., elevating the risk of PC metastasis and compromising the efficacy of radiotherapy, chemotherapy, and anti-PD-1/PD-L1 immunotherapy. Notably, the CCLx-CCR2 and CXCLx-CXCR2/4 axis emerge as potential therapeutic targets in PC. This review integrates recent findings on chemokines and receptors in PC treatment, offering valuable insights for innovative therapeutic approaches.

Role of CXCL12/CXCR4 Signaling Axis in Pancreatic Cancer.

Cxcl12/Cxcr4 Axis Plays Pivotal Roles in the Organ-Specific Metastasis of Pancreatic Adenocarcinoma: A Clinical Study

Mechanisms by Which CXCR4/CXCL12 Cause Metastatic Behavior in Pancreatic Cancer

The role of CXCL12/CXCR4 axis in interaction between pancreatic cancer and neural cells

Cxcl12-Cxcr4 Chemotactic Pathway Modulates Metastasis And Perineural Invasion In Pancreatic Cancer

Abstract A22: CXCL12-CXCR4 chemotactic pathway modulates metastasis and perineural invasion in pancreatic cancer

The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer.

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

The Critical Roles of Activated Stellate Cells-Mediated Paracrine Signaling, Metabolism and Onco-Immunology in Pancreatic Ductal Adenocarcinoma

Aberrant Expression of CXCR4 and Β-Catenin in Pancreatic Cancer.

Blockade of SDF-1/CXCR4 Signalling Inhibits Pancreatic Cancer Progression in Vitro Via Inactivation of Canonical Wnt Pathway.

Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer

CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target

The role of CXCL12 in tumor microenvironment

Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell

Stromal-derived Factor-1Α/cxcl12-cxcr4 Chemotactic Pathway Promotes Perineural Invasion in Pancreatic Cancer.

Targeting CXCL5 in Pancreatic Cancer Cells Inhibits Cancer Xenograft Growth by Reducing Proliferation and Inhibiting EMT Progression

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications